Traws Pharma, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3
Traws Pharma, Inc. (TRAW) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 of -$4.86 million for the 3-month period ending 2017-06-30, per its 10-Q filed 2017-11-09.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 · last filed 2017-11-09
- Traws Pharma, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for the quarter ending 2017-06-30 was -$4.86M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 6 month |
|---|---|---|
| 2017-06-30 | -$4.86M 10-Q · filed 2017-11-09 | -$4.86M 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |